Dynamic Changes in Nevi of a Patient With Melanoma Treated With Vemurafenib
Open Access
- 1 October 2012
- journal article
- observation
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 148 (10), 1183-1185
- https://doi.org/10.1001/archdermatol.2012.2649
Abstract
BackgroundTherapy with vemurafenib, an inhibitor of mutated BRAF, yields a response rate of approximately 50% in patients with metastatic melanoma harboring a BRAF V600E mutation. As an adverse effect of vemurafenib, proliferative disorders of keratinocytes, including squamous cell carcinoma, have been described. Low concentration of vemurafenib as present in the epidermis were found to activate wild-type RAF, which, in combination with a preexisting RAS mutation, can promote keratinocyte proliferation. While activating BRAF mutations occur in approximately 50% of melanomas, they are even more frequently observed in melanocytic nevi.ObservationWe present the case of a patient with dynamic changes of melanocytic nevi well documented by sequential digital dermoscopy during vemurafenib therapy. A variety of dermoscopic changes were observed. First, nevi involuted, and all of these originally showed a centrally elevated papillomatous and predominant globular pattern. Second, preexisting nevi increased in size, and pigmentation that rendered them atypical. Such lesions were flat and showed a predominant reticular pattern at baseline. Third, multiple new nevi occurred. One example of each of the latter 2 categories was excised and showed wild-type BRAF.ConclusionOur findings of changing nevi in a patient treated with vemurafenib highlight the need for sequential skin examinations, including dermoscopy.Keywords
This publication has 9 references indexed in Scilit:
- RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsYearbook of Pathology and Laboratory Medicine, 2013
- Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionJournal of Clinical Oncology, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibThe New England Journal of Medicine, 2012
- RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF InhibitorsJournal of Clinical Oncology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Faculty Opinions recommendation of Improved survival with vemurafenib in melanoma with BRAF V600E mutation.Published by H1 Connect ,2011
- The Dermoscopical and Histopathological Patterns of Nevi Correlate with the Frequency of BRAF MutationsJournal of Investigative Dermatology, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- High frequency of BRAF mutations in neviNature Genetics, 2002